Healthcare professionals are involved in the detection, monitoring, management and treatment of chronic disease conditions such as diabetes. The American Diabetes Association (ADA) has stated that early detection is critical to improving disease outcomes.
In early 2013 Freedom Meditech received FDA clearance for the first-in-class CLEARPATH DS-120 device that detects autofluorescence of the crystalline lens of the eye. In independent scientific studies published in peer-reviewed journals, elevated autofluorescence measurements have been linked to high levels of advanced glycosylated end products, which accumulate in the presence of diabetes and uncontrolled glucose over time.
Our market research indicates that the eye care provider is an ideal health professional to screen for diabetes:
If you would like to participate in our no-obligation clinical program, please contact us at 858-638-1433.